January 18, 2022
Article
Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.
January 17, 2022
Article
The recent approval of sotorasib for the treatment of patients with advanced KRAS G12C–mutant non–small cell lung cancer marks a milestone for cancer therapy.
January 14, 2022
Article
Oncology Live®
Patient education in oncology can often be daunting and complicated for clinicians and patients.
January 13, 2022
Article
Christopher S. Lathan, MD, MS, MPH, discusses the lack of dissemination and implementation of evidence-based health care delivery innovations focused on addressing disparities in care.
January 12, 2022
Article
Oncology Live®
High expression of activated leukocyte cell adhesion molecule, also known as CD166, occurs in approximately 50% of patients with triple-negative breast cancer and up to 80% of patients with estrogen receptor– positive, HER2-negative breast cancer.
January 11, 2022
Article
Oncology Live®
When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.
January 10, 2022
Article
Oncology Live®
It is difficult to know where exactly to begin this commentary regarding the FDA approval to permit commer-cial sales of the Alzheimer disease drug aducanumab-avwa.